Engineering the Specificity of Antibacterial Fluoroquinolones: Benzenesulfonamide Modifications at C-7 of Ciprofloxacin Change Its Primary Target in Streptococcus pneumoniae from Topoisomerase IV to Gyrase

@article{Alovero2000EngineeringTS,
  title={Engineering the Specificity of Antibacterial Fluoroquinolones: Benzenesulfonamide Modifications at C-7 of Ciprofloxacin Change Its Primary Target in Streptococcus pneumoniae from Topoisomerase IV to Gyrase},
  author={F. Alovero and Xiao-Su Pan and Julia E. Morris and R. Manzo and L. Fisher},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2000},
  volume={44},
  pages={320 - 325}
}
  • F. Alovero, Xiao-Su Pan, +2 authors L. Fisher
  • Published 2000
  • Biology, Medicine
  • Antimicrobial Agents and Chemotherapy
ABSTRACT We have examined the antipneumococcal mechanisms of a series of novel fluoroquinolones that are identical to ciprofloxacin except for the addition of a benzenesulfonylamido group to the C-7 piperazinyl ring. A number of these derivatives displayed enhanced activity againstStreptococcus pneumoniae strain 7785, including compound NSFQ-105, bearing a 4-(4-aminophenylsulfonyl)-1-piperazinyl group at C-7, which exhibited an MIC of 0.06 to 0.125 μg/ml compared with a ciprofloxacin MIC of 1… Expand
Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases
TLDR
NXL101 inhibited topoisomerase IV more effectively than gyrase from Escherichia coli, whereas the converse is true of enzymes from Staphylococcus aureus, indicating apparent target preference is opposite to that which is associated with most fluoroquinolone antibiotics. Expand
Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro
TLDR
The data suggest that gemifloxacin is an enhanced affinity fluoroquinolone that acts against gyrase and topoisomerase IV in S. pneumoniae, with gyrases the preferred in vivo target. Expand
Contributions of the 8-Methoxy Group of Gatifloxacin to Resistance Selectivity, Target Preference, and Antibacterial Activity against Streptococcus pneumoniae
TLDR
It is hypothesized that the 8-methoxy group of gatifloxacin increases the level of target inhibition, especially against DNA gyrase, so that it is nearly the same as that for topoisomerase IV inhibition in the bacterial cell, leading to potent antibacterial activity and a low level of resistance selectivity. Expand
Ciprofloxacin Dimers Target Gyrase in Streptococcus pneumoniae
TLDR
Although a dimer molecule could bind very tightly by bridging quinolone binding sites in the enzyme-DNA complex, the greater potency of ciprofloxacin against gyrase and topoisomerase IV suggests that dimers 1 to 3 bind in a monomeric fashion. Expand
Small-Colony Mutants of Staphylococcus aureus Allow Selection of Gyrase-Mediated Resistance to Dual-Target Fluoroquinolones
TLDR
It is proposed that small-colony mutations unbalance target sensitivities, perhaps through altered ATP or topoisomerase levels, such that gyrase becomes the primary drug target. Expand
Comparative study of new benzenesulphonamide fluoroquinolones structurally related to ciprofloxacin against selected ciprofloxacin-susceptible and -resistant Gram-positive cocci.
TLDR
A high degree of correlation was found between the MICs of the new compounds and ciprofloxacin for Staphylococcus spp. Expand
Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureus
TLDR
Although gemifloxacin targets purified topoisomerase IV and gyrase similarly in vitro, topoisomersase IV is the preferred target in the bacteria. Expand
Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.
TLDR
The resistance selection frequencies of levofloxacin were higher than those of moxifloxAcin at concentrations equivalent to those at the end of the dosing interval, therefore mox ifloxACin may have less of an impact on the development of resistance than levof loxac in comparison with other fluoroquinolones. Expand
Mechanisms of Quinolone Action
TLDR
The bacteriostatic effects of the quinolones are now understood at a level sufficient to allow structure-function interpretations and from a clinical perspective, there is a need to identify safe compounds that rapidly kill bacteria, especially resistant mutants. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
TLDR
The results indicate that resistance to fluoroquinolones in S. pneumoniae occurs in vitro at a low frequency, involving sequential mutations in topoisomerase IV and DNA gyrase and within clinically achievable levels in the blood and lungs of humans. Expand
DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae
  • Xiao-Su Pan, L. Fisher
  • Biology, Medicine
  • Antimicrobial Agents and Chemotherapy
  • 1998
TLDR
The results suggested that clinafloxacin displays comparable if unequal targeting of gyrase and topoisomerase IV and its first- and second-step mutants are desirable features in limiting the emergence of bacterial resistance. Expand
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus
TLDR
Findings provide direct genetic evidence that topoisomersase IV is the primary target of current fluoroquinolones in S. aureus and that this effect may result from the greater sensitivity of topoisomerase IV relative to that of DNA gyrase to these agents. Expand
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
TLDR
In both laboratory strains and clinical isolates, ParC mutations preceded those in GyrA, suggesting that topoisomersase IV is a primary topoisomerase target and gyrase is a secondary target for ciprofloxacin in S. pneumoniae. Expand
Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: dramatic differential effects on mammalian topoisomerase II and DNA gyrase
TLDR
The cis- and trans-methyl substitutions on the piperazine that conferred potency against the mammalian type II enzyme had little effect on bacterial DNA gyrase cleavage activity, suggesting that an asymmetric barrier exists with the mammalian enzyme which influences productive quinolone interaction. Expand
Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus
TLDR
It is demonstrated that mutations in gyrA or mutations leading to reduced drug accumulation occur after alteration of GrlA, supporting the previous findings that DNA topoisomerase IV is a primary target of fluoroquinolones in S. aureus. Expand
Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones
TLDR
It is shown that the Ser-83----Trp mutation in the gyrase A protein was solely responsible for high-level bacterial resistance to nalidixic acid and fluoroquinolones. Expand
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro
TLDR
Data strongly suggest that ParC is the primary target for fluoroquinolones in S. pneumoniae and that BM4205-R3 is resistant to higher levels of the drugs following the acquisition of two mutations, including one in gyrA. Expand
Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential
TLDR
The cytotoxicity of quinolones in the CP-115,953 series towards mammalian cells paralleled the in vitro stimulation of DNA cleavage by topoisomerase II rather than the inhibition of enzyme-catalyzed DNA relaxation, which strongly suggests that these qu inolones promote cell death by converting topoisomersase II to a cellular poison. Expand
ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
TLDR
Transformation experiments suggest that ParC is the primary target of ciprofloxacin, and mutation in parC appears to be a prerequisite before mutations in gyrA can influence resistance levels. Expand
...
1
2
3
4
...